Tumour‐associated macrophage‐mediated survival of myeloma cells through STAT3 activation |
| |
| Authors: | Nathan De Beule Kim De Veirman Ken Maes Elke De Bruyne Eline Menu Karine Breckpot Hendrik De Raeve Rian Van Rampelbergh Jo A Van Ginderachter Rik Schots Karin Vanderkerken |
| |
| Affiliation: | 1. Laboratory of Haematology and Immunology, Myeloma Centre Brussels, Vrije Universiteit Brussel, Brussels, Belgium;2. Laboratory of Molecular and Cellular Technology, Vrije Universiteit Brussel, Brussels, Belgium;3. Department of Pathology, Universitair Ziekenhuis Brussel, Brussels, Belgium;4. Laboratory of Cellular and Molecular Immunology, Vrije Universiteit Brussel, Brussels, Belgium;5. Myeloid Cell Immunology Laboratory, VIB Inflammation Research Centre, Ghent, Belgium;6. Department of Clinical Haematology, Universitair Ziekenhuis Brussel, Brussels, Belgium;7. Laboratory of Haematology and Immunology, Myeloma Centre Brussels, Vrije Universiteit Brussel, Brussels, BelgiumEqual contributions. |
| |
| Abstract: | Overcoming drug resistance is one of the greatest challenges in the treatment of multiple myeloma (MM). The interaction of myeloma cells with the bone marrow (BM) microenvironment is a major factor contributing to drug resistance. Tumour‐associated macrophages (TAMs) with different polarization states constitute an important component of this microenvironment. Previous studies have revealed a role of TAMs in MM cell survival and drug resistance; however, the impact of macrophage polarization (anti‐tumoural ‘M1’ versus pro‐tumoural ‘M2’‐like phenotype) in this process has not yet been described. Here, the presence of TAMs was confirmed in BM sections from MM patients, both at diagnosis and relapse, with two M2 markers, CD163 and CD206. By following different TAM subpopulations during disease progression in the syngeneic murine 5T33MM model, we demonstrated a decrease in the number of inflammatory monocytes and an increase in the number of M2‐oriented TAMs in BM. Co‐culture experiments demonstrated that macrophages provide a survival benefit to myeloma cells that is maintained after treatment with several classes of anti‐myeloma agent (melphalan and bortezomib); the greatest effect was observed with M2‐polarized macrophages. The pro‐survival effect was associated with activation of the STAT3 pathway in 5T33MM cells, less cleavage of caspase‐3, and thus less apoptosis. AZD1480, an ATP‐competitive JAK2 inhibitor, abrogated the observed TAM‐mediated MM cell survival, and partially inhibited resistance to bortezomib. Despite having only a small quantitative impact on myeloid cells in vivo, AZD1480 treatment alone and in combination with bortezomib significantly reduced tumour load. In conclusion, M2 TAMs are present in the MM microenvironment, and contribute to MM cell survival and protection from drug‐induced apoptosis. As a result of TAM‐induced activation of the STAT3 pathway, 5T33MM cells are sensitized to AZD1480 treatment. Copyright © 2016 Pathological Society of Great Britain and Ireland. Published by John Wiley & Sons, Ltd. |
| |
| Keywords: | multiple myeloma tumour‐associated macrophages drug resistance STAT3 |
|
|
